Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Kura Oncology, Inc.
Condition: Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT02464228
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.